AM

Amicogen, Inc.

Biotech firm using enzyme tech for pharma, healthcare, and bioprocess CDMO services.

092040 | KO

Overview

Corporate Details

ISIN(s):
KR7092040005
LEI:
Country:
South Korea
Address:
경상남도 진주시 문산읍 월아산로950번길 14-10 아미코젠 문산 1공장, 진주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Amicogen, Inc. is an industrial biotechnology company founded in 2000 that specializes in the research, development, and production of special enzymes and other bio-new materials. Leveraging its core enzyme technology, the company provides solutions for the pharmaceutical and healthcare sectors. Its business areas include developing functional ingredients for health and nutrition through its KNUTRA brand, producing cell culture media, and offering Contract Development and Manufacturing Organization (CDMO) services for the bioprocess industry. Amicogen is focused on creating sustainable value for human health and the environment through continuous innovation and R&D.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-18 00:00
Share Issue/Capital Change
전환가액의조정 (제4회차)
Korean 10.6 KB
2025-09-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-20 00:00
Regulatory News Service
불성실공시법인지정 (공시변경)
Korean 6.0 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.3 MB
2025-08-11 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제6회차 CB)
Korean 5.6 KB
2025-08-01 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 49.8 KB
2025-07-30 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (대여금 청구-취하)
Korean 7.0 KB
2025-07-28 00:00
Legal Proceedings Report
소송등의제기ㆍ신청(일정금액이상의청구)
Korean 7.3 KB
2025-07-25 00:00
Regulatory News Service
불성실공시법인지정예고
Korean 4.9 KB
2025-07-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-25 00:00
Regulatory News Service
[기재정정]신규시설투자등
Korean 12.1 KB
2025-05-23 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.9 MB

Automate Your Workflow. Get a real-time feed of all Amicogen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Amicogen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Amicogen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.